RGNX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Regenxbio Inc. (RGNX) is not a good buy at the moment for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock is facing significant regulatory challenges, negative sentiment from lawsuits, and reduced analyst price targets. Despite some positive financial trends, the risks outweigh the potential rewards, especially given the investor's preference for long-term stability.
The MACD is positive and expanding, suggesting mild bullish momentum. However, the RSI is neutral at 53.167, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its resistance level of 8.685, with key support at 7.752. Overall, the technical indicators do not strongly support a buy signal.
Revenue increased by 22.88% YoY in Q3 2025, showing growth in top-line performance.
Gross margin improved significantly to 80.75%, up 65.44% YoY, indicating operational efficiency.
FDA's Complete Response Letter (CRL) for RGX-121 has created regulatory uncertainty and delayed potential revenue streams.
Class action lawsuits alleging misleading information about RGX-111 have added legal and reputational risks.
Analyst price targets have been significantly reduced across the board, reflecting diminished confidence in the stock.
Negative sentiment in the news and options market, with a high Option Volume Put-Call Ratio of 17.17, indicates bearish sentiment.
In Q3 2025, revenue increased by 22.88% YoY to $29.73M, and gross margin improved to 80.75%. However, net income remains negative at -$61.94M, and EPS is at -1.2, showing only slight improvement YoY. The company is still far from profitability.
Analysts have lowered their price targets significantly, with Morgan Stanley reducing it to $18, Goldman Sachs to $12, and others like Baird and H.C. Wainwright maintaining buy ratings but with reduced targets. The sentiment is cautious, with concerns over regulatory hurdles and legal risks overshadowing potential long-term opportunities.
